Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Castleman Disease Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
suramin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab, Placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
8
States / cities
La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
Interventions
CNTO 328
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Little Rock, Arkansas • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions
Zidovudine, Tocilizumab, Valganciclovir (VGC)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced May 21, 2026, 7:39 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node
Interventions
Sample Collection
Other
Lead sponsor
Castleman Disease Collaborative Network
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Castleman's Disease, Angiofollicular Lymph Hyperplasia, Giant Lymph Node Hyperplasia
Interventions
Blood draw/buccal swab
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 7:39 PM EDT
Suspended Not applicable Interventional
View directory record Official record
Conditions
Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH), Non-Langerhans-Cell Histiocytosis
Interventions
Genetic testing
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Multicentric
Interventions
Sirolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Little Rock, Arkansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma, Primary Effusion
Interventions
Daratumumab SC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Castleman's Disease
Interventions
tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced May 21, 2026, 7:39 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma
Interventions
CX-4945 oral formulation
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
HIV, Kaposi's Sarcoma, Lymphomas, Multicentric Castleman's Disease, Primary Effusion Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Lansing, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Multicentric Castleman s Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Multicentric Castleman's Disease
Interventions
Siltuximab
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced May 21, 2026, 7:39 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Kaposi Sarcoma, Gastric Cancer, Nasopharyngeal Cancer, EBV, Castleman Disease
Interventions
Nelfinavir
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition, Precancerous Condition
Interventions
tanespimycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced May 21, 2026, 7:39 PM EDT